Related Experiment Video

Updated: May 28, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer

G V Koukourakis1, A Sotiropoulou-Lontou

  • 1Second Radiation Therapy Department, Saint Savvas Anticancer Institute of Athens, Greece. gkoyokoyrakis@yahoo.gr

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|October 7, 2011
PubMed

Insights

Targeted therapies like bevacizumab offer new hope for metastatic colorectal cancer (CRC) by inhibiting tumor growth. This review highlights bevacizumab

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapies represent a significant advancement in cancer treatment, stemming from a deeper understanding of cancer cell development.
  • These therapies selectively target molecular pathways crucial for tumorigenesis and tumor progression.
  • Angiogenesis, vital for tumor growth and metastasis, is a key target for novel biological agents.

Purpose of the Study:

  • To review the efficacy of bevacizumab in treating metastatic colorectal cancer (CRC).
  • To discuss the role of targeted therapies in improving outcomes for colon cancer patients.

Main Methods:

  • Review of scientific literature on bevacizumab and its mechanism of action.
  • Analysis of clinical data regarding the use of bevacizumab in metastatic CRC.

Main Results:

  • Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis by blocking vascular endothelial growth factor (VEGF) receptor binding.
  • FDA approval in 2004 marked bevacizumab as a first-line treatment for metastatic CRC.
  • Integration of targeted therapies, including bevacizumab, has led to significant improvements in treatment efficacy for colon cancer.

Conclusions:

  • Bevacizumab demonstrates significant efficacy in the treatment of metastatic colorectal cancer.
  • Targeted therapies are crucial for advancing the treatment landscape of colon cancer.
  • Further research into targeted agents continues to improve patient outcomes in oncology.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...